← back to search

Marie‐Ange Mouret‐Reynier

Centre Jean Perrin · FR
🔎 Find collaborators in Oncology · Cancer Research →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, and HER2/EGFR in Cancer Research.
h-index
41
citations
7,783
works
193
NIH funding
primary concept
Medicine
email

Recent publications

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine 2025cited by 79position: middledoi
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
New England Journal of Medicine 2024cited by 382position: middledoi
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Journal of Clinical Oncology 2023cited by 100position: middledoi
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
2023cited by 14position: contributordoi
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology 2022cited by 676position: middledoi
Genomics to select treatment for patients with metastatic breast cancer
Nature 2022cited by 166position: middledoi
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Nature Medicine 2021cited by 154position: middledoi
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
JAMA Oncology 2021cited by 81position: middledoi
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
The Lancet Oncology 2020cited by 160position: middledoi
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology 2017cited by 381position: middledoi
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
PLoS Medicine 2016cited by 404position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Olivier Trédan · Institut de Cancérologie de l'Ouest2 papers (2021–2023)Sibel Blau · Northwest Medical Specialties1 papers (2017–2017)Mona El-Hashimy · Novartis (Switzerland)1 papers (2017–2017)Joyce O’Shaughnessy · Baylor University Medical Center1 papers (2024–2024)Alain Lortholary · Hôpital Tenon1 papers (2021–2021)Éric Pujade-Lauraine · Hospital Universitario Ramón y Cajal1 papers (2021–2021)Xuan Zhou · University of Edinburgh1 papers (2024–2024)Vassiliki Karantza · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2024–2024)Claire Falandry · Institute of Aging1 papers (2021–2021)Eva Ciruelos · Breast Cancer Research Foundation1 papers (2017–2017) · 1 papers (2021–2021)Ruth O’Regan · University of Wisconsin–Madison1 papers (2017–2017) · 1 papers (2021–2021)Gilles Freyer · Eau de Paris (France)1 papers (2021–2021)Laëtitia Stefani · University of Verona1 papers (2021–2021)Yeon Hee Park · The Catholic University of Korea Daejeon St. Mary's Hospital1 papers (2024–2024) · 1 papers (2024–2024)Charles Coutant · Centre Georges François Leclerc1 papers (2023–2023)Angelo Di Leo · International Breast Cancer Study Group1 papers (2017–2017)Javier Cortes · National Cancer Centre Japan1 papers (2024–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Cancer Research →